| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
No direct biological target; the compound is a phosphoramidite building block for oligonucleotide synthesis. The 2'-O-methyl modification, when incorporated into oligonucleotides, enhances nuclease resistance and binding affinity. The DMT group protects the 5'-hydroxyl during synthesis, and the Bz group protects the cytosine amino group.
|
|---|---|
| ln Vitro |
The compound itself has no biological activity as it is a synthetic building block. Upon incorporation into oligonucleotides, the 2'-O-methyl modification enhances nuclease resistance and improves target binding affinity. Oligonucleotides containing this modification are used in therapeutic and research applications.
|
| ln Vivo |
Not applicable; the compound is a synthetic building block with no direct in vivo activity. Oligonucleotides synthesized using this building block may have in vivo activity depending on the sequence and target. The 2'-O-methyl modification improves the pharmacokinetic properties of oligonucleotides.
|
| Enzyme Assay |
Not applicable for the phosphoramidite. For oligonucleotide synthesis, standard solid-phase phosphoramidite chemistry is used. The compound is coupled to a growing oligonucleotide chain, oxidized, and capped. After synthesis, the oligonucleotide is deprotected and purified. The final product is characterized by HPLC, mass spectrometry, and other methods.
|
| Cell Assay |
Cells are not typically treated directly with this phosphoramidite. The compound is used in chemical synthesis of modified oligonucleotides. The final oligonucleotides may be tested in cellular assays for target knockdown, nuclease resistance, and biological activity.
|
| Animal Protocol |
Not applicable; the compound is a synthetic building block not used directly in animal studies. Oligonucleotides synthesized using this building block may be tested in animal models for therapeutic applications such as antisense therapy or RNAi.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for the phosphoramidite are not applicable. Oligonucleotides containing 2'-O-methyl modifications have improved pharmacokinetic properties, including increased nuclease resistance and longer half-life. The compound has a molecular weight of 663.71 and formula C38H37N3O8.
|
| Toxicity/Toxicokinetics |
Toxicology data for the phosphoramidite have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling chemical intermediates should be observed.
|
| References | |
| Additional Infomation |
DMT-2'-OMe-Bz-C (CAS: 110764-74-4, molecular formula C38H37N3O8, molecular weight 663.71) is a protected nucleoside building block. It is used for manufacturing 2'-O-methylated oligonucleotides including siRNAs and ASOs. The 2'-O-methyl modification protects against enzymatic degradation. It is not in clinical trials.
|
| Molecular Formula |
C38H37N3O8
|
|---|---|
| Molecular Weight |
663.72
|
| Exact Mass |
663.258
|
| CAS # |
110764-74-4
|
| PubChem CID |
13872214
|
| Appearance |
White to off-white solid powder
|
| Density |
1.27±0.1 g/cm3(Predicted)
|
| LogP |
4.629
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
49
|
| Complexity |
1130
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)O
|
| InChi Key |
WXJKGOQQYUVNQW-YDXJMRNDSA-N
|
| InChi Code |
InChI=1S/C38H37N3O8/c1-45-29-18-14-27(15-19-29)38(26-12-8-5-9-13-26,28-16-20-30(46-2)21-17-28)48-24-31-33(42)34(47-3)36(49-31)41-23-22-32(40-37(41)44)39-35(43)25-10-6-4-7-11-25/h4-23,31,33-34,36,42H,24H2,1-3H3,(H,39,40,43,44)/t31-,33-,34-,36-/m1/s1
|
| Chemical Name |
N-[1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~150.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5067 mL | 7.5333 mL | 15.0666 mL | |
| 5 mM | 0.3013 mL | 1.5067 mL | 3.0133 mL | |
| 10 mM | 0.1507 mL | 0.7533 mL | 1.5067 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
